Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 23, 2010. The filing serves to announce the company's financial and operational results for the fiscal year ended December 31, 2009. The registrant is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text. Consequently, no specific financial metrics can be extracted from this document alone.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the full year 2009 results. Any year-over-year comparisons or significant operational shifts are located in the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The text contains no management commentary, forward-looking guidance, or specific risk factors. It includes a standard legal disclaimer stating that the information in this report and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the March 23, 2010 press release), as they are absent from the 8-K text.
- Confirm the company name is PharmAthene, Inc., noting the discrepancy with the "Altimmune, Inc." label in the request metadata.
- Review the full press release for any operational milestones or clinical trial updates associated with the 2009 fiscal year.
- Check subsequent filings to see if the 2009 results were incorporated by reference into later registration statements.